Pricing Log in Create free account

Longeveron Inc. (LGVN) vs Xenetic Biosciences, Inc. (XBIO)

Longeveron Inc. and Xenetic Biosciences, Inc. are both Biotechnology companies. Longeveron Inc. and Xenetic Biosciences, Inc. are of similar size ($4.8M and $4.7M). Xenetic Biosciences, Inc. grew revenue faster over the last twelve months: 33.3% against −42.7%. Xenetic Biosciences, Inc. has the higher net margin (−75.9% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 18 metrics below, Xenetic Biosciences, Inc. leads on 13 and Longeveron Inc. on 5.

Valuation

Metric LGVN XBIO Biotechnology median
P/E n/m n/m 8.50
P/S 3.67 1.39 9.71
P/B 0.42 0.75 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.22 0.30 0.64
EV/Sales (4.16) (0.24) 9.21
Earnings yield (712.23%) (58.59%) (33.15%)
Free cash flow yield (477.81%) (50.87%) (25.50%)

Profitability

Metric LGVN XBIO Biotechnology median
Gross margin 69.76% 100.00% 65.16%
Operating margin (1,992.84%) (81.01%) 0.00%
Net margin (1,977.59%) (75.90%) 0.00%
Free cash flow margin (1,755.69%) (70.93%) 0.00%
Return on equity (203.61%) (47.05%) (56.36%)
Return on assets (145.64%) (40.17%) (48.04%)
Return on invested capital (4,549.04%) 0.00% 0.00%

Growth

Metric LGVN XBIO Biotechnology median
Revenue growth (TTM) (42.74%) 33.30% 6.02%
EPS growth (last fiscal year) 50.76% 38.52% 30.26%
Revenue growth, 5-year CAGR (26.60%) 46.78% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LGVN XBIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.63 7.43 4.72
Net debt to EBITDA 0.20 2.78 0.96

Dividend

Metric LGVN XBIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LGVN XBIO Biotechnology median
Market cap 4.79m 4.71m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack